![share_log](https://usnewsfile.moomoo.com/20230625000012291e57d0213b0.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
牛牛AI助理已提取核心訊息
Bristol-Myers Squibb (BMS) reported a 5% increase in total revenues for the first quarter of 2024, reaching $11.865 billion compared to $11.337 billion in the same period of 2023. However, the company experienced a significant decrease in GAAP diluted earnings per share (EPS), reporting a loss of $5.89 per share in 2024 against a profit of $1.07 per share in 2023. The non-GAAP diluted loss per share was $4.40 for the first quarter of 2024, compared to earnings of $2.05 per share in 2023. The decline in EPS was primarily attributed to higher one-time Acquired IPRD charges from recent acquisitions, particularly the Karuna asset acquisition and SystImmune collaboration. BMS's business development has been robust, with significant advances in the CAR-T cell therapy arena, approvals for multiple myeloma treatments...Show More
Bristol-Myers Squibb (BMS) reported a 5% increase in total revenues for the first quarter of 2024, reaching $11.865 billion compared to $11.337 billion in the same period of 2023. However, the company experienced a significant decrease in GAAP diluted earnings per share (EPS), reporting a loss of $5.89 per share in 2024 against a profit of $1.07 per share in 2023. The non-GAAP diluted loss per share was $4.40 for the first quarter of 2024, compared to earnings of $2.05 per share in 2023. The decline in EPS was primarily attributed to higher one-time Acquired IPRD charges from recent acquisitions, particularly the Karuna asset acquisition and SystImmune collaboration. BMS's business development has been robust, with significant advances in the CAR-T cell therapy arena, approvals for multiple myeloma treatments Abecma and Breyanzi, and expanded approvals for oncology drug Reblozyl. The company completed acquisitions of Karuna, RayzeBio, and Mirati, and entered into strategic collaborations with SystImmune and Cellares to bolster its pipeline and manufacturing capabilities. Looking ahead, BMS is executing a strategic productivity initiative aimed at achieving $1.5 billion in annual cost savings by the end of 2025, with the majority of savings to be reinvested in innovation and growth. The company remains focused on strategic business development, maintaining a strong investment grade credit rating, growing dividends, and reducing debt.
施貴寶(BMS)報告稱,2024年第一季度總收入增長5%,達到118.65億美元,較2023年同期的113.37億美元增加;然而,公司的每股收益(EPS)大幅下降,報告2024年每股虧損5.89美元,而2023年每股收益爲1.07美元。 第一季度的非通用會計準則稀釋虧損每股爲4.40美元,而2023年每股收益爲2.05美元。 EPS下降主要歸因於最近收購中獲得的一次性獲得無形資產及研發開支,特別是Karuna資產收購和SystImmune公司的合作。 BMS的業務發展一直保持強勁,CAR-T細胞治療領域取得重大進展,多發性骨髓瘤治療藥物Abecma和Breyanzi獲得批准,腫瘤學藥物Rebl...展開全部
施貴寶(BMS)報告稱,2024年第一季度總收入增長5%,達到118.65億美元,較2023年同期的113.37億美元增加;然而,公司的每股收益(EPS)大幅下降,報告2024年每股虧損5.89美元,而2023年每股收益爲1.07美元。 第一季度的非通用會計準則稀釋虧損每股爲4.40美元,而2023年每股收益爲2.05美元。 EPS下降主要歸因於最近收購中獲得的一次性獲得無形資產及研發開支,特別是Karuna資產收購和SystImmune公司的合作。 BMS的業務發展一直保持強勁,CAR-T細胞治療領域取得重大進展,多發性骨髓瘤治療藥物Abecma和Breyanzi獲得批准,腫瘤學藥物Reblozyl獲得擴展批准。 公司完成了對Karuna、RayzeBio和Mirati的收購,並與SystImmune和Cellares建立了戰略合作關係,以增強其管道和製造能力。 展望未來,BMS正在執行戰略生產力計劃,旨在實現到2025年底的15億美元年度成本節約,其中大部分節約將重新投資於創新和增長。 公司仍專注於戰略業務發展,保持強有力的投資信用評級,增加股息並減輕債務負擔。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了